Nuvo Pharmaceuticals Inc MRVFF

RE: RE: RE: RE: I'll Keep Asking.....

[Cdninvstr]

Thanks for the response JD121. I must have been looking at the "coles notes" version of the 3rd quarter results. I am less hopeful that Covidien will step up in the short term to secure more unlicensed countries. I say this because Covidien was more proactive in brokering the original deal with Nuvo especially given that Pennsaid was not even FDA approved at the time of the deal and I truly believe that Covidien was as surprised as most of us were that Pennsaid was approved without further delays. I'm a little dubious of the notion that Covidien will need to hire 100 or more sales reps to push Pennsaid. I figured a few extra "brand" managers specifically focused on the marketing of Pennsaid and the same sales team with a new drug to peddle when they make their calls..not that 100 more reps
selling the product hurts.
Not sure what the shelf life is for Pennsaid, but would be encouraged to get some type of feedback from Nuvo regarding the necessary ramp up in production for Pennsaid, in order to satisfy the additional requirement to stock American pharmacies...samples to doctors...etc. Like I've said in the past, it would not be misleading for Nuvo management to update shareholders that Pennsaid production has increased.
Granted that past Nuvo management was guilty of  " over-promising and under-delivering", let's not be stifled by the new strategy of " under-promising and over-delivering".
I'm truly hoping for a dark-horse to enter the fray...request marketing rights for other unlicensed countries...and force Covidien to get off the fence and buy Nuvo outright.
Perhaps Glaxo or Ranbaxy will take a shot at owning Nuvo...maybe all three will fight over it.